Grifols (GRFS) & Its Rivals Financial Contrast

Grifols (NASDAQ:GRFS) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Grifols to similar companies based on the strength of its dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Insider & Institutional Ownership

47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 0.2% of Grifols shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for Grifols and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1	2	0	0	1.67
Grifols Competitors	9773	15031	45238	1571	2.54

Grifols presently has a consensus target price of $9.00, suggesting a potential upside of 11.11%. As a group, “Biotechnology” companies have a potential upside of 95.57%. Given Grifols’ rivals stronger consensus rating and higher probable upside, analysts plainly believe Grifols has less favorable growth aspects than its rivals.

Earnings and Valuation

This table compares Grifols and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Grifols	$8.51 billion	$454.82 million	42.63
Grifols Competitors	$722.78 million	$12.25 million	-10.12

Grifols has higher revenue and earnings than its rivals. Grifols is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Grifols has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, Grifols’ rivals have a beta of 1.14, meaning that their average share price is 14% more volatile than the S&P 500.

Dividends

Grifols pays an annual dividend of $0.09 per share and has a dividend yield of 1.1%. Grifols pays out 47.4% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 1.4% and pay out 58.4% of their earnings in the form of a dividend.

Profitability

This table compares Grifols and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Grifols Competitors	-9,054.29%	-198.66%	-30.54%

Summary

Grifols rivals beat Grifols on 8 of the 15 factors compared.

Grifols Company Profile

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.